Ligand Pharmaceuticals Incorporated· LGND

🇺🇸 US · MidSP600NASDAQ

HealthcareBiotechnologyWebsite

Price: $300.79
Day: +3.00%
Mkt Cap: $6.03B
52W Range: $132.21 – $326.63
Volume: 303.5K
Beta: 0.98

D25D FrameworkTTM Data

Peer Comparison

Performance vs sector and industry peers across 40 metrics.

Blog

stockoscope.com

Ligand Pharmaceuticals Incorporated

LGND|Healthcare|Biotechnology

Comparing against 139 sector peers in United States · Mid Cap · Healthcare

Peer Comparison

Dimension 2 of 5

Revenue Growth

84%ile

51.2%

Operating Margin

95%ile

36.7%

ROIC

63%ile

5.6%

FCF Yield

62%ile

2.0%

Growth & Cash Flow Quality

Percentile ranking across profitability growth and cash generation

EBITDA Growth

-282.0%

EBIT Growth

-219.3%

Net Income Growth

-215.8%

OCF Growth

133.8%

FCF Growth

246.4%

Income Quality

0.80

Returns on Capital (TTM)

ROE(16.2%)

74%ile

Above Avg

PoorWeakAdequateStrongExceptional

ROCE(6.8%)

63%ile

Above Avg

PoorWeakAdequateStrongExceptional

ROA(10.0%)

84%ile

Top 20%

PoorWeakAdequateStrongExceptional

ROIC(5.6%)

63%ile

Above Avg

PoorWeakAdequateStrongExceptional

Profit Margins (TTM)

Gross Margin(N/A)

N/A

PoorWeakAdequateStrongExceptional

EBITDA Margin(81.0%)

100%ile

Top 20%

PoorWeakAdequateStrongExceptional

Operating Margin(36.7%)

95%ile

Top 20%

PoorWeakAdequateStrongExceptional

Net Margin(56.0%)

99%ile

Top 20%

PoorWeakAdequateStrongExceptional

Leverage & Coverage (TTM)

Debt/Equity

39%ile

0.45

Debt/Capital

39%ile

0.31

Net Debt/EBITDA

43%ile

1.52

Interest Coverage

55%ile

21.51x

Liquidity (TTM)

Current Ratio

88%ile

21.3

Quick Ratio

88%ile

21.0

Cash Ratio

69%ile

2.83

WC Turnover

37%ile

0.34

Operational Efficiency (TTM)

Asset Turnover

16%ile

0.18

DSO

24%ile

72.9

Days Inventory

N/A

Cash Conv. Cycle

N/A

TTM: Trailing Twelve Months · EBITDA: Earnings Before Interest, Taxes, Depreciation & Amortization · EBIT: Earnings Before Interest & Taxes · ROA: Return on Assets · ROIC: Return on Invested Capital · ROCE: Return on Capital Employed · ROE: Return on Equity · OCF: Operating Cash Flow · FCF: Free Cash Flow · DSO: Days Sales Outstanding · WC: Working Capital

See the complete picture

The full 5D Framework: Business Quality · Peer Comparison · Valuation · Analyst Sentiment · Smart Money

Explore LGND on stockoscope.com→

Generated August 5, 2026

For educational purposes only. Not financial advice. Data may be delayed or incomplete.

139 sector peers (United States · Mid Cap · Healthcare)

Relative Quality

LGND Relative Quality Score

Ranked against 139 sector peers in United States · Mid Cap · Healthcare

Relative Quality

3.4/5

Adequate

vs 139 sector peers

Peer Rankings (9 of 10 available)

Relative Quality Score of 3.35/5 (Adequate) based on percentile rankings against 139 sector peers in United States · Mid Cap · Healthcare. Each pillar shows a 1-5 score plus the cohort percentile (e.g. 95p = top 5%); higher percentiles indicate stronger relative performance.Last updated August 4, 2026.

Top-Line and Profit Growth

How does the company's growth rate compare to peers?

Revenue Growth

84th percentile, Exceptional

Value: 51.24%
Percentile: 84%
Score: 5/5

PoorWeakAdequateStrongExceptional

Analysis

LGND has a ttm revenue growth of 51.24% and ranks at the 84th percentile vs United States · Healthcare sector peers. Top-tier financial performance.

Margin Efficiency

Does the company maintain better profit margins than peers?

No data for Gross Margin is available for LGND, so peer comparison is hidden for this metric. Try another metric.

Operational Efficiency

Is the company more operationally efficient than competitors?

Asset Turnover

16th percentile, Poor

Value: 0.18
Percentile: 16%
Score: 1/5

PoorWeakAdequateStrongExceptional

Analysis

LGND has a ttm asset turnover of 0.18 and ranks at the 16th percentile vs United States · Healthcare sector peers. Poor financial performance.

Returns Overview

Does the company generate better returns on capital than peers?

ROA

84th percentile, Exceptional

Value: 10.02%
Percentile: 84%
Score: 5/5

PoorWeakAdequateStrongExceptional

Analysis

LGND has a ttm roa of 10.02% and ranks at the 84th percentile vs United States · Healthcare sector peers. Top-tier financial performance.

Cash Flow Quality

How does the company's cash generation compare to peers?

Operating Cash Flow Growth

93rd percentile, Exceptional

Value: 133.76%
Percentile: 93%
Score: 5/5

PoorWeakAdequateStrongExceptional

Analysis

LGND has a ttm operating cash flow growth of 133.76% and ranks at the 93rd percentile vs United States · Healthcare sector peers. Top-tier financial performance.

Liquidity and Working Capital

Does the company maintain better liquidity positions than competitors?

Cash Ratio

69th percentile, Strong

Value: 2.83
Percentile: 69%
Score: 4/5

PoorWeakAdequateStrongExceptional

Analysis

LGND has a ttm cash ratio of 2.83 and ranks at the 69th percentile vs United States · Healthcare sector peers. Strong financial performance.

Leverage and Coverage

Is the company's debt burden more manageable than peers?

Debt to Capital

39th percentile, Weak

Value: 0.31
Percentile: 39%
Score: 2/5

PoorWeakAdequateStrongExceptional

Analysis

LGND has a ttm debt-to-capital of 0.31 and ranks at the 39th percentile vs United States · Healthcare sector peers. Below average financial performance.

Valuation Multiples

Is the company's stock valuation attractive relative to peers?

P / E Ratio

43rd percentile, Adequate

Value: 38.37
Percentile: 43%
Score: 3/5

PoorWeakAdequateStrongExceptional

Analysis

LGND has a ttm p/e ratio of 38.37 and ranks at the 43rd percentile vs United States · Healthcare sector peers. Adequate financial performance.

Dividend and Shareholder Yield

Does the company deliver superior income to shareholders compared to peers?

No data for Dividend Yield is available for LGND, so peer comparison is hidden for this metric. Try another metric.

Peer companies

The 140 companies LGND is compared against across its sector and industry cohorts.

Ligand Pharmaceuticals Incorporated· LGND

Peer Comparison

Top-Line and Profit Growth

Per-Share Fundamentals

Margin Efficiency

Operational Efficiency

Returns Overview

Cash Flow Quality

Liquidity and Working Capital

Leverage and Coverage

Valuation Multiples

Dividend and Shareholder Yield

Peer companies

Search stocks

Peer Comparison

Top-Line and Profit Growth

Per-Share Fundamentals

Margin Efficiency

Operational Efficiency

Returns Overview

Cash Flow Quality

Liquidity and Working Capital

Leverage and Coverage

Valuation Multiples

Dividend and Shareholder Yield

Peer companies